Home MarketXLS
Dashboard MarketXLS
Screener MarketXLS
Options Profit Calculator MarketXLS
Stock Ranks MarketXLS
Spreadsheet Builder MarketXLS
Documentation MarketXLS
Logout MarketXLS

EYPT Stock Annual Income Statement. Download in Excel

EyePoint Pharmaceuticals Inc. logo

EyePoint Pharmaceuticals Inc.

Sector: Healthcare   

Industry: Biotechnology

8.93
 
USD
  
-0.01
  
(-0.11%)
Previous close: 8.94  Open: 9.17  Bid: 8.85  Ask: 9.1
52 week range    
3.91   
   13.99
Mkt Cap: 559 M  Avg Vol (90 Days): 817,222
Last updated: Tuesday 10th June 2025

Stock Rankings

59
MarketXLS Rank
60
Value
83
Technical
36
Quality
How are these ranks calculated?
Financials

EYPT Income Statement

Annual
Invalid dateDec-20Dec-21Dec-22Dec-23Dec-24
Amortization of intangibles3 M3 M2 M
Basic EPS from continuing operations-3.54-2.03-2.74-1.82-2.32
Basic EPS total-3.54-2.03-2.74-1.82-2.32
Basic weighted shares outstanding13 M29 M37 M39 M56298.0
Cost of sales8 M500000.04 M
Depreciation189000.0311000.0400000.0500000.02 M
Depreciation unreconciled2 M
DepreciationAndAmortization189000.0311000.02 M500000.02 M
Diluted EPS total-3.54-2.03-2.74-1.82-2.32
Diluted normalized net income/share-2.74-1.82-2.32
Diluted weighted shares outstanding13 M29 M37 M39 M56298.0
GeneralAndAdministrativeExpense21 M26 M35 M40 M52 M
Gross operating profit34 M37 M33 M46 M43 M
ImpairmentOfCapitalAssets21 M
Income before tax-29 M-37 M-102 M-71 M-131 M
Income taxes-3 M-3 M-6 M83000.090000.0
InterestExpenseNonOperating7 M5 M3 M1 M
MiscOtherSpecialCharges-847000.02 M572000.06 M15 M
Net income from total operations-45 M-58 M-102 M-71 M-131 M
NetIncomeCommonStockholders-29 M-37 M-102 M-65 M-131 M
NetIncomeContinuousOperations-45 M-58 M-102 M-71 M-131 M
NetNonOperatingInterestIncomeExpense-7 M-5 M1 M-6 M
Normalized income-40 M-129 M
Operating income-37 M-55 M-100 M-75 M-146 M
Operating income before depreciation (EBITDA)-18 M-29 M-97 M-69 M-129 M
OperatingExpense72 M92 M112 M121 M189 M
Other income net847000.0-2 M-22 M-6 M-15 M
OtherGandA21 M26 M35 M40 M52 M
OtherOperatingExpenses-8 M-11 M-8 M2 M3 M
Research & development expense17 M29 M50 M65 M133 M
ResearchExpense17 M29 M50 M65 M133 M
Revenue per share3 M3 M2 M
SalariesAndWages12 M37 M
Selling Gen & administrative expense46 M53 M60 M52 M52 M
SellingAndMarketingExpense25 M28 M26 M12 M131000.0
Special income/charges-21 M
Total Income available for interest expense (EBIT)-22 M-32 M-99 M-69 M-131 M
Total common shares outstanding29 M34 M34 M50 M69 M
Total net income-45 M-58 M-102 M-71 M-131 M
Total ordinary shares69 M69 M69 M69 M69 M
Total revenues34 M37 M41 M46 M43 M
TotalExpenses72 M92 M120 M122 M189 M
TotalRevenue34 M37 M41 M46 M43 M
Call: 1-877-778-8358
Ankur Mohan MarketXLS
Welcome! I'm Ankur, the founder and CEO of MarketXLS. With more than ten years of experience, I have assisted over 2,500 customers in developing personalized investment research strategies and monitoring systems using Excel.

I invite you to book a demo with me or my team to save time, enhance your investment research, and streamline your workflows.
Implement "your own" investment strategies in Excel with thousands of MarketXLS functions and templates.
MarketXLS provides all the tools I need for in-depth stock analysis. It's user-friendly and constantly improving. A must-have for serious investors.

John D.

Financial Analyst

I have been using MarketXLS for the last 6+ years and they really enhanced the product every year and now in the journey of bringing in AI...

Kirubakaran K.

Investment Professional

MarketXLS is a powerful tool for financial modeling. It integrates seamlessly with Excel and provides real-time data.

David L.

Financial Analyst

I have used lots of stock and option information services. This is the only one which gives me what I need inside Excel.

Lloyd L.

Professional Trader